March 13, 2026
Sharjah, UAE – XCath, a medical device company pioneering neuro-endovascular surgical robotics and partially owned by Crescent Enterprises, has secured $30 million in Series C funding, bringing its total funding since inception to $92 million. The latest capital will support XCath’s mission to bring the world’s first commercially-practical endovascular robot to market and enable clinical telerobotic mechanical thrombectomy procedures.
The funding round was co-led by Crescent Enterprises and Fred Moll, Chairman of the XCath Board of Directors.
Advancing Neurovascular Robotics
“We are grateful to our investors for their conviction in our mission to improve outcomes for patients affected by endovascular diseases,” said Eduardo Fonseca, CEO of XCath. “In 2025, the XCath team advanced the frontiers of endovascular robotics. This funding accelerates our commitment to expanding access to life-saving care, ensuring that a patient’s location no longer determines whether they survive.”
The Series C round follows XCath’s successful clinical procedures using the Iris robotic system to treat complex brain aneurysms in November 2025. Performed by Dr. Vitor Mendes Pereira at The Panama Clinic in collaboration with local Principal Investigator Dr. Anastasio Ameijeiras Sibauste, these procedures marked only the second time in history that a surgical robot was used for an intracranial neurovascular intervention. These milestones reinforce XCath’s leadership in the emerging field of endovascular robotics.
Addressing a Critical Healthcare Need
Stroke and other neurovascular diseases represent one of the largest financial and clinical opportunities in healthcare. XCath’s platform is uniquely positioned to address this unmet need with innovative robotic solutions.
“Robotic surgery succeeds when innovation is paired with practical execution,” said Dr. Moll. “XCath has built a promising technology foundation and a team that values rigor and perspective. I’m excited to support their mission to globalize access to gold-standard care for stroke patients.”
Neeraj Agrawal, XCath Board Member and Crescent Enterprises Executive Director, added:
“Surgical robotics represents one of the most compelling long-term investment opportunities in healthcare. XCath has assembled an exceptional team of physicians, entrepreneurs, and engineers, focused on addressing a significant global healthcare unmet need.”
About XCath
Founded in 2017, XCath operates at the forefront of surgical robotics with campuses in Houston, Texas, home to the world’s largest medical center, and Pangyo, South Korea, known as Korea’s Silicon Valley.
XCath’s Iris system is the only endovascular robotic platform in development capable of intracranial navigation and neurointerventional procedures. It is also the only system to have performed a neurovascular procedure using robotic manipulation of three devices and standard monoplane imaging equipment.
Currently under development, the XCath system is not yet cleared for commercial distribution in any country.
